A randomized, double-blind, placebo-controlled, eventdriven trial of quarterly subcutaneous canakinumab in the prevention of recurrent cardiovascular events among stable post-myocardial infarction patients with elevated hsCRP + save

Date Added
May 28th, 2013
PRO Number
Pro00010103
Researcher
Christopher Nielsen
Keywords
Coronary Artery Disease, Heart
Summary

This study will examine the use of a new agent called canakinumab to treat patients that have had a heart attack and have an elevated hsCRP (substance in the blood that can indicate inflammation in the body).

Institution
MUSC
Recruitment Contact
Christina Creek
(843) 876-5008
russelcm@musc.edu

Study of Access Site for Enhancement of PCI for Women (SAFE-PCI for Women) + save

Date Added
December 11th, 2012
PRO Number
Pro00013457
Researcher
Daniel Steinberg
Keywords
Coronary Artery Disease, Women's Health
Summary

The purpose of this study is to learn whether female patients undergoing a heart catheterization procedure to open a blood vessel(s) experience more success when the procedure is performed through the leg or through the arm. The study is also trying to determine if there is a lower complication rate when this procedure is performed through the leg or through the arm. The study will include 3000 people in the United States.

Institution
MUSC
Recruitment Contact
Suzanne Richardson
843-792-1238
ricsu@musc.edu

PRE-DETERMINE Study: Biologic Markers and Sudden Cardiac Death + save

Date Added
August 21st, 2012
PRO Number
Pro00018255
Researcher
Terrence O'brien
Keywords
Coronary Artery Disease
Summary

Subjects that have previously had a heart attack may be at an increased risk of sudden cardiac death (life-threatening heart rhythm disturbances). This study is looking to identify a series of lab tests that will specifically predict the risk of arrhythmic death in order to work to preventing in the future.

Institution
MUSC
Recruitment Contact
Leslie Harrell
843-789-6138
leslie.harrell@va.gov

A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events with Ticagrelor Compared to Placebo on a Background of Acetyl Salicylic Acid (ASA) Therapy in Patients with History of Myocardial Infarction + save

Date Added
June 22nd, 2011
IRB Number
20631
Researcher
James Thomas
Keywords
Cardiovascular, Circulation, Coronary Artery Disease, Drug Studies
Summary

We are seeking volunteers who have had a heart attack one to three years ago (2008 through 2010).

The drug being studied is ticagrelor, a platelet inhibitor.

The purpose of this study is to determine if the study medication will reduce the chances of another heart attack or stroke.

To qualify for the study you must be at least 50 years old, have had a prior heart attack (see above) and meet certain other criteria.

All lab work, EKG's, physical exams, etc. are provided at no cost.

Compensation is available for travel and expenses.

Institution
MUSC
Recruitment Contact
Aimee L. Tetrault, RN, BSN
843-876-5012
tetrault@musc.edu

COLOR: Chemometric Observations of Lipid Core Containing Plaques of Interest in Native Coronary Arteries Registry + save

Date Added
February 1st, 2011
IRB Number
19221
Researcher
Eric Powers
Keywords
Cardiovascular, Circulation, Coronary Artery Disease, Heart
Summary

For patients requiring a cardiac catheterization using a FDA approved catheter (Liposcan/IVUS) that collects data during the procedure. Patients will recieve follow up phone calls at 30 days, 6 months, 1 year and 2 year intervals.

Institution
MUSC
Recruitment Contact
Christina Russell, RN
843-876-5008
russelcm@musc.edu

Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus: A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients with Type 2 Diabetes + save

Date Added
May 11th, 2010
IRB Number
20033
Researcher
James Thomas
Keywords
Cardiovascular, Coronary Artery Disease, Diabetes, Stroke
Summary

This is a phase 4 trial that is investigating the diabetes drug already approved by the FDA (Onglyza or saxagliptin). The purpose of this study is to see if adding Onglyza to the other medications you are already taking will reduce your risk of cardiovascular disease. You must be over 40 years old and have type II diabetes to be in this study. You will be required to come in for study visits every 6 months. All study visits including lab tests and EKG's are free of charge.

Institution
MUSC
Recruitment Contact
Aimee L. Tetrault, RN, BSN
843-876-5012
tetrault@musc.edu